Patents by Inventor Xin Yang
Xin Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260316267Abstract: The present disclosure provides a main hand control device for a robot, a puncture device, and a robot. The main hand control device includes: a puncture needle execution component, the puncture needle execution component including a rod structure; and an attitude adjustment execution component, the attitude adjustment execution component being configured to obtain an attitude of the rod structure; wherein the rod structure is capable of moving relative to the attitude adjustment execution component along an axial direction of the rod structure.Type: ApplicationFiled: June 4, 2026Publication date: October 15, 2026Applicant: WUHAN UNITED IMAGING SURGICAL CO., LTD.Inventors: Zhuangzhuang LU, Fang WEI, Mingchun ZHAI, Zhuo ZHAO, Xin YANG, Lihong XU
-
Patent number: 12759427Abstract: An electric vehicle charging control device includes an electronic dynamic charging schedule generator, a non-transitory computer readable medium and an electronic communicator. The charging schedule generator has an electronic controller configured to determine when an electric vehicle user accesses a charging port provided at a building structure powered by an electric source. The non-transitory computer readable medium stores vehicle profile data for the electric vehicle. The electronic communicator is configured to receive profile updates to the vehicle profile data from an electronic user interface. The electronic controller is programmed to generate a charging schedule based on the vehicle profile data. The charging schedule has a charge period in which the electric vehicle is receiving charge from the building structure and a discharge period in which the electric vehicle is providing charge to the building structure.Type: GrantFiled: April 28, 2023Date of Patent: October 13, 2026Assignee: NISSAN NORTH AMERICA, INC.Inventors: Najamuddin Mirza Baig, Liam Pedersen, Xin Yang, Anna Baranskaya, Lance Atkins, Kyle Wray
-
Publication number: 20260302133Abstract: A cascade arc plasma generator including a cathode structure, a cascade structure, and an anode structure sequentially connected. When the cascade arc plasma generator works, working gas enters an ionization chamber through a gas inlet channel, a potential difference exists between arc starting pins and an anode body, and the working gas is ionized to form a plasma, which is jetted outside the cascade arc plasma generator through the ionization chamber, a plasma channel, and an anode channel that are connected in sequence, and enters an external device to interact with a material sample. The arc starting pins are parallel to each other and arranged at intervals, and ends of tips thereof are located in a same plane to form a planar plasma source being able to irradiate a large-area material sample or a plurality of material samples at a time.Type: ApplicationFiled: May 16, 2025Publication date: October 1, 2026Inventors: Haishan Zhou, Weiyun Zhou, Xin Yang, Yu Li, Guangnan Luo
-
Publication number: 20260297519Abstract: A CAR-T cell targeting CLL1, and preparation method and use thereof are provided. Specifically, the present application relates to a CAR-T cell, containing a chimeric antigen receptor. The chimeric antigen receptor comprises a single-domain antibody, a hinge region, a transmembrane region, and an intracellular signaling region. The amino acid sequence of the single-domain antibody corresponds to positions 22-150 of SEQ ID No: 1. Experiments demonstrate that the CLL1-VHH-16 CAR-T cell is capable of effectively secreting T-cell-specific effector molecule IFN-?, efficiently and specifically killing CLL1+ target cells, and exhibiting excellent in vivo antitumor activity. The CLL1-VHH-16 CAR-T cell can not only significantly inhibit the proliferation of tumor cells in mice, but also significantly prolong the survival time of the mice. The CLL1-VHH-16 CAR-T cell exhibits excellent antitumor ability, can be used for immunotherapy of CLL1 target-related diseases, and has broad clinical application prospects.Type: ApplicationFiled: December 20, 2023Publication date: October 1, 2026Applicant: CARBIOGENE THERAPEUTICS CO., LTD.Inventors: Xin YANG, Jiangao ZHU, Wenjun YANG, Jiandong YU
-
Patent number: 12738905Abstract: A Radio-Frequency (RF) circuit for an RF front-end includes a balanced amplifier with first and second amplifiers and an output directional coupler. First and second ports of the output directional coupler are coupled to outputs of the first and second amplifiers, a third port of the output directional coupler is coupled to an input-output terminal that is configured to be coupled to an antenna, and a fourth port of the output directional coupler is coupled to an input of a receiver amplifier. In a transmit mode, the output directional coupler may couple an RF signal to the input-output terminal. In a receive mode, the output directional coupler may couple a signal received from an antenna to the input of the receiver amplifier.Type: GrantFiled: October 5, 2023Date of Patent: September 15, 2026Assignee: NXP B.V.Inventors: Xin Yang, Mark Pieter van der Heijden, Jasper Pijl, Zhe Chen
-
Publication number: 20260263522Abstract: A CLL1-CAR-T cell contains a chimeric antigen receptor, which includes a single-domain antibody, a hinge region, a transmembrane region, and an intracellular signaling region. The amino acid sequence of the single-domain antibody corresponds to positions 22-150 of SEQ ID NO: 1. The CLL1-VHH-1 CAR-T cells can effectively secrete the T-cell-specific effector molecule IFN-?, specifically and efficiently kill CLL1+ target cells, and exhibit favorable in vivo anti-tumor activity. They not only significantly inhibit the proliferation of tumor cells in mice but also markedly prolong the survival time of mice. The CLL1-VHH-1 CAR-T cells demonstrate excellent anti-tumor capabilities and can be used for immunotherapy of diseases related to the CLL1 target, such as acute myeloid leukemia, presenting broad prospects for clinical applications.Type: ApplicationFiled: January 4, 2024Publication date: September 10, 2026Applicant: CARBIOGENE THERAPEUTICS CO., LTD.Inventors: Xin YANG, Jiangao ZHU, Wenjun YANG, Jiandong YU
-
Patent number: 12728438Abstract: The present invention discloses an automatic gluing apparatus for a fixed shaft-type rewinding reel, including a gluing mechanism and a glue supply mechanism, where the gluing mechanism includes a mounting plate, a side of the mounting plate is provided with a glue scraping head configured to apply a glue to the rewinding reel, a glue-scraping drive assembly that is configured to drive the glue scraping head to approach or leave the rewinding reel is disposed between the glue scraping head and the mounting plate, and the glue scraping head includes a glue scraping surface fitting with a shape of an outer surface of the rewinding reel; the glue supply mechanism disposed on a side of the mounting plate, connected to the glue scraping head. The gluing mechanism can resolve the inconvenience of the manual gluing operation, improve the efficiency of electrode plate rewinding.Type: GrantFiled: October 22, 2024Date of Patent: September 8, 2026Assignees: Shenzhen Yinghe Technology Co., Ltd., Huizhou Yinghe Technology Co., LtdInventors: Xin Yang, Shuhong Huang, Quanhong Zhang, Pengyun Yang, Shunshun Cai, Shi Wang, Zizhuan Zhang, Xianjin Yi
-
Patent number: 12731035Abstract: Split learning is provided to train a composite neural network (CNN) model that is split into first and second submodels, including receiving a noise-laden backpropagation gradient, training the surrogate submodel by optimizing a gradient distance loss, and computing an updated dummy label using the first submodel and the trained surrogate submodel to infer label information of the second submodel. Noise can be added to a label of the second submodel or a shared backpropagation gradient to protect the label information.Type: GrantFiled: January 3, 2023Date of Patent: September 8, 2026Inventors: Shangyu Xie, Jiankai Sun, Xin Yang, Yuanshun Yao, Tianyi Liu, Taiqing Wang
-
Patent number: 12722524Abstract: A battery swap apparatus and a battery swap system relating to the field of battery swap for electrical devices is disclosed. The battery swap apparatus includes a floating platform, a locking and unlocking mechanism and an positioning mechanism. The locking and unlocking mechanism is arranged on the floating platform, and the positioning mechanism is arranged on the floating platform. The positioning mechanism includes a positioning member and a driving member. The driving member is configured to drive the positioning member to move in a height direction of the battery swap apparatus, so as to adjust the height of the positioning member. The driving member drives the positioning member to move downwardly to reduce the height of the positioning member The driving member drives the positioning member to move upwardly to increase the height of the positioning member.Type: GrantFiled: November 1, 2023Date of Patent: September 1, 2026Assignee: CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITEDInventors: Disong Chen, Yuanhe Wu, Qingfeng Ye, Ling Shuai, Xin Yang
-
Publication number: 20260248967Abstract: The present invention provides an adeno-associated virus (AAV) vector and use thereof. The AAV vector comprises a nucleic acid fragment encoding a secreted tat-degradation peptide. The AAV vector designed in the present invention can be continuously expressed in the peripheral nervous system, where the expressed degradation peptides can cross the blood-brain barrier and cell membranes to exert long-term therapeutic effects in central nervous system (CNS) diseases. Additionally, the vector can also be continuously expressed in the CNS, where the degradation peptides cross the cell membrane to mediate its effects in both AAV-infected and non-infected cells. Therefore, the present invention offers an AAV vector that enables widespread and long-acting delivery of a therapeutic degradation peptide.Type: ApplicationFiled: May 11, 2023Publication date: August 27, 2026Inventors: Xin Yang, Tian Tian, Yu Tian Wang
-
Publication number: 20260253395Abstract: An image dataset processing method includes acquiring an initial autonomous driving image dataset; inputting the initial autonomous driving image dataset into a first autonomous driving detection model to obtain a first image detection result and inputting the initial autonomous driving image dataset into a second autonomous driving detection model to obtain a second image detection result; comparing the first image detection result with the second image detection result to obtain a comparison result; determining a comparison type based on the comparison result; determining evaluation scores of the multiple initial autonomous driving images based on the comparison type; and selecting a target autonomous driving image dataset from the initial autonomous driving image dataset based on the evaluation scores of the multiple initial autonomous driving images and adjusting at least one annotation in the target autonomous driving image dataset.Type: ApplicationFiled: March 29, 2024Publication date: August 27, 2026Applicant: Chengdu Kawa Technology Co., Ltd.Inventors: Qian XU, Xin YANG, Nan JIA, Guangyin XIONG
-
Publication number: 20260242486Abstract: Single-domain antibodies binding to the CLL1 protein and their uses are provided. Specifically, a single-domain antibody with the amino acid sequence of SEQ ID NO: 1 is provided. This single-domain antibody exhibits high affinity and can effectively and specifically target CLL1-positive cells. It can efficiently promote the secretion of IFN? by NK cells, activate the effector functions of NK cells, and significantly induce the cytotoxic effects of NK cells, thereby demonstrating a strong capacity for specifically killing CLL1-positive cells. The single-domain antibody can be formulated into drugs for the clinical prevention or treatment of diseases related to the CLL1 target. It can also be used for the preparation of CAR cells targeting CLL1 or detection kits for the CLL1 protein. The single-domain antibody drug features stable structure, small molecular size, ease of recombinant expression, and low production costs.Type: ApplicationFiled: March 30, 2023Publication date: August 20, 2026Applicant: CARBIOGENE THERAPEUTICS CO., LTD.Inventors: Xin YANG, Jiangao ZHU, Wenjun YANG
-
Publication number: 20260244895Abstract: The present disclosure provides a fusion training method for a risk control model, including: receiving label data, and refining expert knowledge; separately performing multi-order feature crossing on the label data and the expert knowledge, to obtain a data representation and a rule representation; purifying the data representation based on the rule representation; and training and outputting the risk control model based on the purified data representation.Type: ApplicationFiled: May 19, 2023Publication date: August 20, 2026Inventors: Jing ZHOU, Le LV, Xing FU, Ningtao WANG, Xin YANG, Yang YANG, Chenzhi JIANG, Fangqing LIU, Weiqiang WANG
-
Publication number: 20260229755Abstract: Symmetric spiral configurations of portions of a negative trace and a positive trace with opposite orientations provide for a field cancellation effect in a Wilkinson power divider (or combiner), wherein magnetic fields produced by the positive trace are substantially cancelled out by magnetic fields produced by the negative trace. The geometries of the positive trace and the negative trace effectively produce isolation inductors. Some implementations utilize a transformer, which includes a first positive input port and a first negative input port, an amplifier, and a transformer, which include an input shunt inductor of the differential power divider as part of the transformer.Type: ApplicationFiled: October 20, 2025Publication date: August 6, 2026Inventors: Mark Pieter van der Heijden, Leo Lucas Lancon, Xin Yang, Sebastien Pruvost
-
Publication number: 20260221027Abstract: A system and method for determining improved target speeds for accelerated cruise control systems of vehicles. Data is obtained by human-operated ego vehicles, the data including ego-vehicle speeds, lead-vehicle speeds, follow distances, and location tuples of the ego vehicles, such as GNSS coordinates. The location tuples are mapped to lane centerpoints of a high-definition map. A machine-learning model is trained to determine target speeds of a future vehicle based on the ego-vehicle speeds, lead-vehicle speeds, follow distances, and lane centerpoints. The trained model can be implemented as part of an accelerated cruise control system in a vehicle.Type: ApplicationFiled: January 29, 2025Publication date: July 30, 2026Inventors: Xin Yang, Yuxuan Li, Hirotaka Kamimura, Katsuhiko Hirayama
-
Patent number: 12693681Abstract: An autonomous mobile device (AMD) moves within in a physical space. The AMD may encounter features in the physical space, such as flooring transitions, or obstacles that may impede movement. Sensors such as an ultrasonic sensor, optical time of flight sensors, inertial measurement unit (IMU), wheel speed sensors, and motor torque sensors acquire sensor data. Based on the sensor data, a location of an obstacle, and characterize whether that obstacle is traversable or non-traversable, is determined. If traversable, the AMD may continue moving past the obstacle. If non-traversable, the location of the obstacle may be added to a map used for route planning. Based on the location of the non-traversable obstacle, the AMD may move to a recovery location away from the obstacle, and resume moving.Type: GrantFiled: March 29, 2024Date of Patent: July 28, 2026Assignee: AMAZON TECHNOLOGIES, INC.Inventors: Shreekant Gayaka, Chang Young Kim, Xin Yang
-
Publication number: 20260207744Abstract: A fusion protein with the amino acid sequence of SEQ ID NO: 1 and the nucleic acid molecule (SEQ ID NO: 3) including an encoding gene of a chimeric antigen receptor and an encoding gene of a chimeric switch receptor are provided. By designing fusion gene containing the encoding gene of the chimeric antigen receptor and the encoding gene of the chimeric switch receptor, PD-L1 activated inhibition of anti-tumor T cell responses is converted into a CD27-mediated activation signal, thereby endowing CAR-T cells with the capability of resisting an immunosuppressive tumor microenvironment, thereby enhancing its in vivo persistence. In addition, the micro-environment near a tumor is regulated by promoting secretion of cytokines IFN-? and IFN-?2 to relieve the immunosuppression thereof, thereby mobilizing the organism autoimmunity to participate in the killing effect on tumor cells, and improving the anti-tumor effect of the CAR-T cells.Type: ApplicationFiled: November 28, 2022Publication date: July 23, 2026Applicant: CARBIOGENE THERAPEUTICS CO., LTD.Inventors: Jiangao ZHU, Xin YANG, Wenjun YANG
-
Publication number: 20260209338Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.Type: ApplicationFiled: April 9, 2026Publication date: July 23, 2026Inventors: Wei Zheng, Wubin Pan, Xin Yang, Yang Chen, Limin Zhang, Jie Jiang
-
Patent number: 12687856Abstract: An autonomous mobile device (AMD) moves within in a physical space. The AMD may encounter features in the physical space, such as flooring transitions, or obstacles that may impede movement. Sensors such as an ultrasonic sensor, optical time of flight sensors, inertial measurement unit (IMU), wheel speed sensors, and motor torque sensors acquire sensor data. Based on the sensor data, a location of an obstacle, and characterize whether that obstacle is traversable or non-traversable, is determined. If traversable, the AMD may continue moving past the obstacle. If non-traversable, the location of the obstacle may be added to a map used for route planning. Based on the location of the non-traversable obstacle, the AMD may move to a recovery location away from the obstacle, and resume moving.Type: GrantFiled: March 29, 2024Date of Patent: July 21, 2026Assignee: AMAZON TECHNOLOGIES, INC.Inventors: Shreekant Gayaka, Chang Young Kim, Xin Yang
-
Patent number: 12688322Abstract: A method and apparatus for protecting data, and a device and a medium are provided. The method comprises acquiring, by a first device, a feature representation generated by a second device on the basis of sample data and according to a second model, wherein the first device has label information for the sample data; and the first device and the second device are used for jointly training a first model at the first device and the second model at the second device. The method further comprises generating, by the first device, a prediction label for the sample data on the basis of the feature representation and according to the first model. The method further comprises determining, by the first device and on the basis of the feature representation, the label information and the predicted label, a total loss value used for training the first model and the second model.Type: GrantFiled: February 2, 2023Date of Patent: July 21, 2026Assignee: Lemon Inc.Inventors: Jiankai Sun, Xin Yang, Yuanshun Yao, Junyuan Xie, Chong Wang